Vikram Thermo Peer Comparison

BSE: 530477

₹382.65

₹-18.60 (-4.64%)

As on 19-Oct-2026IST

Market cap

₹1,200 Cr

Revenue (TTM)

₹144 Cr

P/E Ratio

27.4

P/B Ratio

7.1

Div. Yield

0.3 %

Edit

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	1,200	30,978	25,888	26,649	24,655
Revenue (₹ Cr)	144	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	43.84	414.00	-371.81	387.35	288.22
Net Margin (%)	29.86	11.23	-3.93	26.01	14.79
RoE (%)	29.80	8.38	-3.85	25.18	29.77
Price to Earnings	27.37	75.74	--	69.00	85.54
Price-To-Book	7.05	6.15	3.23	15.45	18.37

Income Statement (₹ Cr)

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	144.30	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	146.79	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	83.70	2,792.00	8,195.15	919.25	1,485.56
EBITDA	60.60	772.00	1,010.13	542.56	450.24
Depreciation	3.15	226.00	857.51	37.68	50.83
EBIT	57.46	546.00	152.62	504.88	399.41
Interest	0.45	217.00	342.73	3.77	40.84
Other Income	2.49	122.00	244.31	27.45	12.78
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	59.49	463.00	-162.68	528.56	371.35
Provision for Tax	15.65	49.00	209.13	141.21	83.14
Profit after Tax	43.84	414.00	-371.81	387.35	288.22

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	156.87	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	5.26	1,712.00	5,044.14	42.40	202.03
Current Liabilities	25.78	1,622.00	4,758.28	230.82	835.87
Total Liabilities	201.23	8,578.00	17,723.32	1,983.96	2,326.71

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	57.07	5,343.00	10,211.52	1,026.85	519.60
Current Assets	85.04	2,606.00	7,191.66	881.27	1,681.81
Total Assets	201.23	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	4.59	2,125.00	5,495.48	26.49	259.37
Net Current Assets	59.27	984.00	2,433.38	650.46	845.94
Contingent Liabilities	33.89	768.26	95.72	17.25	19.09

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	51.58	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	-41.48	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	-5.41	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	4.69	95.00	787.59	30.33	78.39

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	36.43	6.79	1.24	32.42	29.22
ROE (%)	29.80	8.38	-3.85	25.18	29.77
ROA (%)	26.27	4.94	-2.21	21.93	24.77
EBIT Margin (%)	39.82	15.32	1.66	34.54	20.63
Net Margin (%)	29.86	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	16.66	18.37	0.78	40.90	46.65
EBIT Growth (%)	39.44	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	37.29	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	33.61	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	29.16	13.47	0.33	26.03	144.31

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	27.37	77.74	-82.73	69.00	84.23
Price / Book Value	7.05	6.15	3.23	15.45	18.37
Dividend Yield (%)	0.33	0.00	0.00	0.08	0.10
EV/EBITDA	19.44	42.02	29.73	48.75	54.57
Market Cap (₹ Cr)	426.78	19,071.62	18,108.89	20,944.75	12,753.19

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.02	0.31	0.53	0.02	0.11
Short term debt to equity ratio	--	0.09	0.09	0.02	0.05
Current Ratio	3.30	1.61	1.51	3.82	2.01
Quick Ratio	2.90	1.06	0.87	2.82	1.14
Interest Coverage	132.03	3.13	0.53	141.16	10.09

	Vikram Thermo	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	31.86	16.50	23.44	24.80	26.28
Asset Turnover	0.86	0.43	0.55	0.83	1.66
Receivable days	122.77	58.75	78.20	88.98	40.13
Inventory Days	28.51	75.82	93.30	56.04	60.29
Payable days	95.88	186.21	226.14	99.95	232.47
Cash Conversion Cycle	55.40	-51.64	-54.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.